ACA
SNDX icon

Avoro Capital Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Avoro Capital Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,275,000
Closed -$30.1M – 40
2024
Q4 		$30.1M Sell
2,275,000
-1,613,437
-41% -$27.6M 0.43% 31
2024
Q3 		$74.9M Hold
3,888,437
– – 1.09% 20
2024
Q2 		$79.8M Sell
3,888,437
-333,785
-8% -$6.99M 1.06% 23
2024
Q1 		$100M Hold
4,222,222
– – 1.17% 22
2023
Q4 		$91.2M Buy
4,222,222
+1,666,667
+65% +$25.6M 1.26% 20
2023
Q3 		$37.1M Sell
2,555,555
-94,445
-4% -$1.79M 0.58% 24
2023
Q2 		$55.5M Hold
2,650,000
– – 0.75% 23
2023
Q1 		$56M Hold
2,650,000
– – 0.83% 20
2022
Q4 		$67.4M Buy
2,650,000
+427,778
+19% +$9.98M 1.01% 19
2022
Q3 		$53.4M Hold
2,222,222
– – 0.99% 18
2022
Q2 		$42.8M Buy
2,222,222
+1,722
+0.1% +$28.7K 0.84% 22
2022
Q1 		$38.6M Buy
2,220,500
+45,500
+2% +$766K 0.7% 22
2021
Q4 		$47.6M Buy
2,175,000
+630,000
+41% +$11.6M 0.81% 20
2021
Q3 		$29.5M Sell
1,545,000
-1,455,000
-49% -$24.2M 0.46% 31
2021
Q2 		$51.5M Buy
3,000,000
+500,000
+20% +$9.16M 0.9% 25
2021
Q1 		$55.9M Buy
2,500,000
+2,050,000
+456% +$46.3M 0.97% 22
2020
Q4 		$10M Buy
+450,000
New +$9.33M 0.17% 40

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Avoro Capital Advisors's SNDX Position: Q1 2025 in Review

Avoro Capital Advisors sold out of Syndax Pharmaceuticals (SNDX) in Q1 2025, closing a stake of 2,275,000 shares — an estimated $30.1M sold.

Avoro Capital Advisors first reported a position in SNDX in Q4 2020 and held it in 17 quarters. The position peaked at $100M in Q1 2024. 218 funds tracked by Wall St. Rank hold SNDX as of Q1 2025.

  • Avoro Capital Advisors reported no remaining Syndax Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Avoro Capital Advisors sold 2,275,000 Syndax Pharmaceuticals shares in Q1 2025, an estimated $30.1M.
  • Avoro Capital Advisors first reported a position in Syndax Pharmaceuticals in Q4 2020 and held it in 17 quarters.
  • Avoro Capital Advisors's Syndax Pharmaceuticals position peaked at $100M in Q1 2024.
  • 218 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2025.

Based on Avoro Capital Advisors's 13F filing for Q1 2025, filed 15 May 2025.